Soluble and cellmassociated transferrin receptor in lung cancer
1997

Transferrin Receptor in Lung Cancer

Sample size: 54 publication Evidence: moderate

Author Information

Author(s): A Dowlati, M Loo, T Bury, G Fillet, Y Beguin

Primary Institution: University of Liege, School of Medicine, Liege, Belgium

Hypothesis

Can measuring soluble and cell-associated transferrin receptor (TfR) levels in lung cancer patients provide diagnostic value compared to patients with chronic obstructive pulmonary disease (COPD)?

Conclusion

Cell-associated TfR levels in bronchoalveolar lavage fluid may assist in differentiating lung cancer from pneumonia.

Supporting Evidence

  • Cell-associated TfR levels were significantly higher in BAL fluid of NSCLC patients than in COPD patients (P = 0.01).
  • A combination of BAL supernatant NSE and cell-associated TfR detected lung cancer with a sensitivity of 91%.
  • The calculated number of TfR molecules per cell in BAL correlated positively with the percentage of macrophages in BAL (P < 0.0001).
  • No correlation existed between BAL cell-associated TfR and tumour size, nodal status, or presence of metastases.

Takeaway

Doctors can check a special protein in the lungs to help tell if someone has lung cancer or just a lung infection.

Methodology

The study measured soluble and cell-associated TfR in serum and bronchoalveolar lavage fluid from lung cancer and COPD patients using ELISA.

Limitations

The study had a limited number of patients, which may affect the generalizability of the results.

Participant Demographics

32 lung cancer patients (23 NSCLC, 9 SCLC) and 22 COPD patients, mostly heavy smokers, with a mean age of 66 for lung cancer and 62 for COPD.

Statistical Information

P-Value

0.01

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication